NOTICE
TO READERS: The press releases, presentations,
printed remarks, footage and publications that
are included on our website are for historical
purposes only. The information contained in these
materials should be considered accurate only as
of the date of the relevant item. This information
may change over time, and visitors to this website
should not assume that the information contained
in these materials remains accurate at a later
time. Oculus Innovative Sciences, Inc. disclaims
any intention to supplement, update or revise any
of the information contained in these materials.
Archived
Press Releases
....................................................................................................................................................................................
These press releases about Oculus Incorporated are sorted
by date, with the most recent at the top. You will need
the free Adobe®
Reader® to view the PDFs. 2008
March 28, 2008
Oculus
Innovative Sciences, Inc., Announces $13.9 Million
Securities Offering
March 27, 2008
Oculus
Innovative Sciences Receives Chinese SFDA Regulatory
Approval of Microcyn® Technology
March 17, 2008
Oculus
Innovative Sciences Announces Positive Results From
Three Abstracts Evaluating the Use of Microcyn® Technology
in Diabetic Foot Ulcers
March 14, 2008
Oculus
Innovative Sciences Announces Additional Phase II
Data for Microcyn® Technology in Mildly Infected
Diabetic Foot Ulcers
March 12, 2008
Oculus
Innovative Sciences Announces Acceptance of Three
Abstracts on the use of Microcyn® Technology
in Diabetic Foot Ulcers by DFCon 08
March 11, 2008
Oculus
Innovative Sciences to Announce Additional Phase
II Data and Data from Two Recent International Studies
at DFCon 08
February 27, 2008
Oculus
Innovative Sciences Schedules Conference Call Today
to Discuss Positive Top-Line Phase II Data with Microcyn® Technology
in Mildly Infected Diabetic Foot Ulcers
February 27, 2008
Oculus
Innovative Sciences Announces Positive Top-Line Phase
II Data with Microcyn® Technology in Mildly Infected
Diabetic Foot Ulcers
February 14, 2008
Oculus
Innovative Sciences to Present at the Roth Capital
Partners 20th Annual OC Growth Stock Conference
February 7, 2008
Oculus
Innovative Sciences Announces Fiscal Third Quarter
2008 Quarterly Results and Clinical Update
February 5, 2008
Oculus
Schedules Fiscal Third Quarter 2008 Financial Results
Release and Conference Call
January 29, 2008
Oculus
Innovative Sciences Announces Agreement with Animal
Health International for North American Distribution
of Microcyn®-Based Vetericyn™ Wound Spray
January 24, 2008
Oculus
Innovative Sciences Awarded Damages by Federal Court
in Intellectual Property Rights Litigation
January 22, 2008
Top-Line
Data from Oculus Innovative Sciences' Phase II Trial
to Be Presented at DFCon 08 (Diabetic Foot Global
Conference) on March 14, 2008
January 17, 2008
Oculus
Innovative Sciences, Inc. Appoints Gregg Alton to
its Board of Directors
January 3, 2008
Oculus
Innovative Sciences Completes Patient Treatment and
Follow-up in Its Phase II Clinical Trial in Mildly
Infected Diabetic Foot Ulcers
2007
December 18, 2007
Oculus
Innovative Sciences Announces Completion of Two Randomized
Controlled Clinical Trials of Microcyn® Technology
in China
December 5, 2007
Oculus
Innovative Sciences Completes Enrollment of Phase
II Trial of Microcyn® Technology in Treatment
of Mildly Infected Diabetic Foot Ulcers
November 19, 2007
Oculus
Innovative Sciences Wins Federal Court Ruling in
Intellectual Property Rights Litigation
November 12, 2007
Oculus
Innovative Sciences Announces Fiscal Second Quarter
2008 Quarterly Results and Clinical Update
November 8, 2007
Oculus
Innovative Sciences Schedules Fiscal Second Quarter
2008 Financial Results Release and Conference Call
November 1, 2007
Oculus
Innovative Sciences to Present at SMH Capital Markets
Investor Growth Conference
October 30, 2007
Oculus
Innovative Sciences to Present at Acumen BioFin 9th
Annual Healthcare Conference
October 3, 2007
Oculus
Innovative Sciences to Present at 4th Annual BIO
InvestorForum Conference
September 17,
2007
Oculus
Innovative Sciences Microcyn Technology Data to
be Presented by Researchers at the 47th Interscience
Conference on Antimicrobial Agents and Chemotherapy
September 17,
2007
Oculus
Innovative Sciences Provides Update of Phase II
Study for Microcyn® Technology in Mildly Infected
Diabetic Foot Ulcers
September 14,
2007
Oculus
Innovative Sciences to Conduct Conference Call
Update on Phase II Study of Microcyn® Technology
in Mildly Infected Diabetic Foot Ulcers
September 6, 2007
Oculus
Innovative Sciences to Present at First Albany Capital
Regenerative Technologies Conference
August 29, 2007
Oculus
Innovative Sciences to Present at Roth Capital Partners
2007 New York Conference
August 9, 2007
Oculus
Innovative Sciences Announces Fiscal First Quarter
2008 Financial Results
August 8, 2007
Oculus
Innovative Sciences Announces $10.1 Million Private
Placement of Common Stock
August 3, 2007
Oculus
Innovative Sciences Schedules Fiscal First Quarter
2008 Financial Results Release and Conference Call
June 26, 2007
Oculus
Innovative Sciences Announces Results From Anti-Inflammatory
Study Using Microcyn® Technology
June 18, 2007
Oculus
Innovative Sciences Appoints Vice President of Regulatory
Affairs and Quality
June 13, 2007
Drug
Enhancement Company of America Licenses Oculus' Microcyn®
Technology for Use in First Responder ''Pen-Like''
Applicator
June 7, 2007
Oculus
Announces Fiscal Fourth Quarter and Full Year 2007
Financial Results
June 6, 2007
Oculus
Schedules Fiscal Fourth Quarter and Full Year 2007
Financial Results Release and Conference Call
May 21, 2007
Oculus
Initiates Patient Enrollment in Phase II Study of
Microcyn®
Technology for Treatment of Mild Diabetic Foot
Infections
May 14, 2007
Oculus
Innovative Sciences Microcyn® Technology Presented
in Poster at European Wound Management Association
Conference
May 9, 2007
Oculus
Innovative Sciences to Present at Rodman & Renshaw
Global Healthcare Conference
April 26, 2007
China
Bao Tai, Sinopharm and Lianhua Supermarkets to Distribute
Oculus' Microcyn®-Based Wound Care Solution in
China
April 25, 2007
Oculus
Innovative Sciences, Inc. Appoints Jay E. Birnbaum
to Its Board of Directors
March 29, 2007
Oculus
Announces Initial Sites for Phase II Clinical Trial
of Microcyn® Technology in Treatment of Mild
Diabetic Foot Infections
March 13, 2007
Oculus'
Dermacyn® Wound Care Subject of 33-Patient Study
Published in International Journal of Lower Extremity
Wounds
February 22, 2007
Oculus
Innovative Sciences Announces Fiscal Third Quarter
2007 Results
January 24, 2007
Oculus
Innovative Sciences, Inc. Announces Initial Public
Offering
2006
July 11, 2006
Pharmaceutical
Veteran Michael Wokasch Joins Oculus Innovative Sciences
As Chief Operating Officer
March 8, 2006
Dermacyn®
Wound Care OTC receives FDA clearance for over-the-counter
sales in the United States.
2005
October 4, 2005
Results
of Clinical Study Evaluating Treatment of Diabetic
Foot Ulcers Using Microcyn® Technology Presented
At Stuttgart2005.
June 17, 2005
Oculus
Innovative Sciences Announces Company's First U.S.
Clinical Trial On Humans.
May 18, 2005
Oculus
Innovative Sciences Announces Second FDA 510k Clearance
of Microcyn® Technology.
May 9, 2005
Oculus
Innovative Sciences Announces FDA 510k Clearance
of Microcyn® Technology.
2004
November 24, 2004
Dermacyn™
Wound Care From Oculus Innovative Sciences Receives
CE Mark Approval For Treating Acute and Chronic Wounds
In Europe.
(PDF: 82 KB)
November 19, 2004
European
Facility is Approved for Manufacturing of Revolutionary
Microcyn® Technology.
(PDF: 88 KB)
November 1, 2004
Oculus
Receives Regulatory Approval To Market Dermacyn™
Wound Care in Canada.
May 14, 2004
Oculus
Files 510(K) with FDA for Approval of Microcyn as Wound
Care Dressing.
(PDF: 92 KB)
May 1, 2004
Oculus
Closes Series "A" Round of Financing for $8
Million.
(PDF: 93 KB)
April 16, 2004
Mexican
Ministry of Health Approves Microcyn Technology for
Use in Veterinarian Market.
(PDF: 93 KB)
March 31, 2004
Oculus
Microcyn60 Disinfectant (OMD) Technology Receives CE
Mark Approval as Disinfectant for Non-Critical Medical
Devices in Europe.
(PDF: 94 KB)
January 9, 2004
Oculus
Applies for CE Mark Approval for California Manufacturing
Facility. (Corrected Jan. 11, 2004)
(PDF: 92 KB)
January 9, 2004
Microcyn
Receives Approval as a Sterilant from Mexican Ministry
of Health.
(PDF: 90 KB)
2003
December 19, 2003
Oculus
Completes Incorporation of Legal Entity in the Netherlands
and Prepares for Opening of European Manufacturing Facility
for Microcyn Technology.
(PDF: 92 KB)
November 11, 2003
Oculus
Innovative Sciences Launches Microcyn in Mexico.
(PDF: 94 KB)
October 1, 2003
Oculus
Files for Pre-Investigational Meeting with FDA to Review
Microcyn60 Antiseptic Technology.
(PDF: 90 KB)
September 18, 2003
MicroMed
Consulting Group Announces Strategic Partnership with
Roberts Consulting & Engineering.
(PDF: 92 KB)
September 9, 2003
Oculus
Innovative Sciences Opens European Office as Company
Seeks CE Mark Approval of Microcyn60 Disinfectant and
Antiseptic.
(PDF: 91 KB)
September 9, 2003
Jim
Schutz Joins Oculus Innovative Sciences as General Counsel
and Corporate Secretary.
(PDF: 90 KB)
September 2, 2003
Dr.
Andres Gutierrez of Mexican Ministry of Health Joins
Oculus Advisory Board.
(PDF: 91 KB)
August 28, 2003
Mexico's
Ministry of Health to Initiate Limited Clinical Trials
of Oculus's "L3" Oncology Compound in Treatment
of Cervical Cancer.
(PDF: 92 KB)
August 14, 2003
Oculus
Innovative Sciences Announces Appointment of Executive
Vice President and Director of Business Development.
(PDF: 93 KB)
July 31, 2003
Microcyn60
Disinfectant from Oculus Innovative Sciences Receives
Mexican Ministry of Health Approval.
(PDF: 92 KB) |
